drugset / Trial / NCT02956122
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in participants with acute GvHD with lower GI involvement.
Timeline
- Start
- 2017-04-26
- Primary completion
- 2018-05-03
- Completion
- 2018-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpha 1-Antitrypsin | Protein / enzyme biologic | — | Intravenous |
| Background | Methylprednisolone | Other / unclassified | — | Intravenous |